FIRST SUPPLEMENTAL INDENTURESupplemental Indenture • October 5th, 2022 • Global Blood Therapeutics, Inc. • Pharmaceutical preparations
FIRST SUPPLEMENTAL INDENTURE, dated as of October 5, 2022 (this “Supplemental Indenture”), between Global Blood Therapeutics, Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association (as successor in interest to U.S. Bank National Association), a national banking association organized under the laws of the United States, as trustee (the “Trustee”), to the Indenture, dated as of December 17, 2021 between such parties (the “Indenture”) governing the 1.875% Convertible Senior Notes due 2028 (the “Notes”). All references to the “Indenture” shall be to the Indenture and, as applicable, this Supplemental Indenture.
